DUSA Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 14   

Articles published

DUSA 0.0000
price chart
Buy rating on Sun Pharma, target Rs 980: Motilal Oswal
Dusa Pharma reported sales of Rs 430 crore versus Rs 97.5 crore in FY13 (consolidated for three months) while it turned profitable in FY14 (Rs 23.7 crore vs loss of Rs 4.7 crore in FY13).
Buy Sun Pharma, target Rs 980: Motilal Oswal  MoneyGuru India
Related articles »  
Buy Sun Pharma; target of Rs 944: Firstcall Research
In 2007, Sun Pharma demerged its research company into a separate entity, Sun Pharma Advanced Research which has been listed on Indian stock exchanges.
Related articles »  
Hold Sun Pharma, target Rs 768: SBIcap
In a note to clients, the brokerage said Sun Pharma's 1QF15 results were a surprise despite weak Taro results as other expenses shrunk.
Related articles »  
WeissLaw LLP Investigates Dusa Pharmaceuticals Inc